Stammdaten
Skye Bioscience, Inc., a biopharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100, which is in Phase I trials for the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 that is in preclinical trials to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. was founded in 2012 and is headquartered in San Diego, California.
Unternehmen & Branche
| Name | Skye Bioscience, Inc. |
|---|---|
| Ticker | SKYE |
| CIK | 0001516551 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 32,1 Mio. USD |
| Beta | 2,87 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -55,924,814 | -1.41 | 28,313,633 | 20,024,175 | |
| 2025-09-30 | 10-Q | -12,754,660 | -0.32 | 41,324,289 | 32,836,185 | |
| 2025-06-30 | 10-Q | -17,624,872 | -0.44 | 52,160,911 | 43,676,709 | |
| 2025-03-31 | 10-Q | -11,103,319 | -0.28 | 64,793,240 | 59,250,314 | |
| 2024-12-31 | 10-K | -26,567,123 | -0.73 | 72,763,773 | 68,151,724 | |
| 2024-09-30 | 10-Q | -3,898,297 | -0.10 | 81,535,660 | 75,803,375 | |
| 2024-06-30 | 10-Q | -7,902,816 | -0.20 | 87,261,531 | 72,809,051 | |
| 2024-03-31 | 10-Q | -5,019,531 | -0.18 | 94,835,276 | 78,883,393 | |
| 2023-12-31 | 10-K | -37,644,784 | -5.37 | 11,940,411 | -2,131,818 | |
| 2023-09-30 | 10-Q | -24,945,834 | -3.17 | 15,604,330 | 1,695,258 | |
| 2023-06-30 | 10-Q | -3,111,500 | -0.80 | 2,235,944 | -7,789,198 | |
| 2023-03-31 | 10-Q | -5,167,520 | -1.37 | 4,586,928 | -4,780,569 | |
| 2022-12-31 | 10-K | -19,481,602 | -8.77 | 9,111,072 | -3,008,054 | |
| 2022-09-30 | 10-Q | -3,127,283 | -1.58 | 2,868,821 | -3,284,981 | |
| 2022-06-30 | 10-Q | -3,419,278 | -0.01 | 4,967,473 | -301,822 | |
| 2022-03-31 | 10-Q | -3,043,399 | -0.01 | 7,210,652 | 2,973,092 | |
| 2021-12-31 | 10-K | -8,522,182 | -0.02 | 9,855,088 | 5,864,166 | |
| 2021-09-30 | 10-Q | -1,824,818 | 0.00 | 11,687,095 | 8,264,782 | |
| 2021-06-30 | 10-Q | -2,024,027 | -0.01 | 5,488,104 | 2,271,104 | |
| 2021-03-31 | 10-Q | -2,160,517 | -0.01 | 5,398,699 | 2,478,649 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-08-22 | Schwab Andrew J. | Director, 10% Owner | Open Market Sale | -6,470 | 3.42 | -22,127.40 | -11,1% | |
| 2025-08-22 | Schwab Andrew J. | Director, 10% Owner | Open Market Sale | -163,979 | 3.42 | -560,808.18 | -280,2% | |
| 2025-08-21 | Schwab Andrew J. | Director, 10% Owner | Open Market Sale | -2,314 | 3.57 | -8,260.98 | -4,1% | |
| 2025-08-21 | Schwab Andrew J. | Director, 10% Owner | Open Market Sale | -58,642 | 3.57 | -209,351.94 | -104,6% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.